Business Description
Heron Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US4277461020
Share Class Description:
HRTX: Ordinary SharesDescription
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.4 | |||||
| Equity-to-Asset | -0.18 | |||||
| Debt-to-Equity | -4.46 | |||||
| Debt-to-EBITDA | -9.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -10.98 | |||||
| Beneish M-Score | -3.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2 | |||||
| 3-Year EBITDA Growth Rate | 32.6 | |||||
| 3-Year EPS without NRI Growth Rate | 31.6 | |||||
| 3-Year FCF Growth Rate | 40.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.81 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.42 | |||||
| 9-Day RSI | 39.45 | |||||
| 14-Day RSI | 35.93 | |||||
| 6-1 Month Momentum % | -45.87 | |||||
| 12-1 Month Momentum % | 36.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.28 | |||||
| Quick Ratio | 1.74 | |||||
| Cash Ratio | 0.83 | |||||
| Days Inventory | 410.51 | |||||
| Days Sales Outstanding | 174.9 | |||||
| Days Payable | 51.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.1 | |||||
| Shareholder Yield % | -9.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.19 | |||||
| Operating Margin % | -18.82 | |||||
| Net Margin % | -20.31 | |||||
| FCF Margin % | -6.2 | |||||
| ROA % | -12.61 | |||||
| ROIC % | -35.63 | |||||
| ROC (Joel Greenblatt) % | -34.6 | |||||
| ROCE % | -15.54 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 595 | |||||
| PS Ratio | 1.31 | |||||
| EV-to-EBIT | -13.11 | |||||
| EV-to-EBITDA | -14.89 | |||||
| EV-to-Revenue | 2.09 | |||||
| EV-to-FCF | -33.75 | |||||
| Earnings Yield (Greenblatt) % | -7.63 | |||||
| FCF Yield % | -4.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Heron Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 137.737 | ||
| EPS (TTM) ($) | -0.16 | ||
| Beta | 2.02 | ||
| Volatility % | 102.56 | ||
| 14-Day RSI | 35.93 | ||
| 14-Day ATR ($) | 0.110723 | ||
| 20-Day SMA ($) | 1.3495 | ||
| 12-1 Month Momentum % | 36.15 | ||
| 52-Week Range ($) | 1.04 - 3.93 | ||
| Shares Outstanding (Mil) | 152.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Heron Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Heron Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Heron Therapeutics Inc Frequently Asked Questions
What is Heron Therapeutics Inc(HRTX)'s stock price today?
The current price of HRTX is $1.19. The 52 week high of HRTX is $3.93 and 52 week low is $1.04.
When is next earnings date of Heron Therapeutics Inc(HRTX)?
The next earnings date of Heron Therapeutics Inc(HRTX) is 2025-03-12 Est..
Does Heron Therapeutics Inc(HRTX) pay dividends? If so, how much?
Heron Therapeutics Inc(HRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers